DK524788A - Anvendelse af morphin-antagonister til fremstilling af laegemidler med immunomodulerende og antiviral effekt, isaer til behandling af erhvervede immundefekt-tilstande - Google Patents

Anvendelse af morphin-antagonister til fremstilling af laegemidler med immunomodulerende og antiviral effekt, isaer til behandling af erhvervede immundefekt-tilstande

Info

Publication number
DK524788A
DK524788A DK524788A DK524788A DK524788A DK 524788 A DK524788 A DK 524788A DK 524788 A DK524788 A DK 524788A DK 524788 A DK524788 A DK 524788A DK 524788 A DK524788 A DK 524788A
Authority
DK
Denmark
Prior art keywords
preparation
treatment
acquired
immundefect
conditions
Prior art date
Application number
DK524788A
Other languages
English (en)
Other versions
DK524788D0 (da
Inventor
Marc Yves Franck Clemen Shelly
Original Assignee
Marc Yves Franck Clemen Shelly
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marc Yves Franck Clemen Shelly filed Critical Marc Yves Franck Clemen Shelly
Publication of DK524788D0 publication Critical patent/DK524788D0/da
Publication of DK524788A publication Critical patent/DK524788A/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/35—Corticotropin [ACTH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK524788A 1987-01-21 1988-09-21 Anvendelse af morphin-antagonister til fremstilling af laegemidler med immunomodulerende og antiviral effekt, isaer til behandling af erhvervede immundefekt-tilstande DK524788A (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8700670A FR2609632B1 (fr) 1987-01-21 1987-01-21 Nouvelle application therapeutique de la 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinon-6-one et les compositions pharmaceutiques destinees a cet usage
PCT/FR1988/000032 WO1988005297A1 (fr) 1987-01-21 1988-01-21 Utilisation d'antagonistes de la morphine dans la preparation de medicaments a effet immunomodulateur et anti-viral, destines notamment a traiter les etats immuno-deficitaires acquis

Publications (2)

Publication Number Publication Date
DK524788D0 DK524788D0 (da) 1988-09-21
DK524788A true DK524788A (da) 1988-11-18

Family

ID=9347124

Family Applications (1)

Application Number Title Priority Date Filing Date
DK524788A DK524788A (da) 1987-01-21 1988-09-21 Anvendelse af morphin-antagonister til fremstilling af laegemidler med immunomodulerende og antiviral effekt, isaer til behandling af erhvervede immundefekt-tilstande

Country Status (9)

Country Link
EP (1) EP0278821B1 (da)
JP (1) JPH02502278A (da)
AT (1) ATE112488T1 (da)
AU (1) AU610561B2 (da)
DE (1) DE3851711D1 (da)
DK (1) DK524788A (da)
FR (1) FR2609632B1 (da)
OA (1) OA09124A (da)
WO (1) WO1988005297A1 (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5095035A (en) * 1981-07-31 1992-03-10 Eby Iii George A Flavor stable zinc acetate compositions for oral absorption
US4877791A (en) * 1988-11-01 1989-10-31 Baker Cummins Pharmaceuticals, Inc. Method of treatment for interestitial cystitis
US4857533A (en) * 1988-12-15 1989-08-15 Baker Cummins Pharmaceuticals, Inc. Method of treatment for autoimmune diseases
US4863928A (en) * 1989-01-04 1989-09-05 Baker Cummins Pharmaceuticals, Inc. Method of treatment for arthritic and inflammatory diseases
RU2058553C1 (ru) * 1994-03-18 1996-04-20 Иван Николаевич Головистиков Способ определения супрессорного звена иммунного статуса человека
RU2056852C1 (ru) * 1994-03-18 1996-03-27 Иван Николаевич Головистиков Средство для лечения аутоиммунных заболеваний с иммунодефицитом супрессоров и способ лечения аутоиммунных заболеваний
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
ATE510534T1 (de) * 2002-03-14 2011-06-15 Euro Celtique Sa Naltrexonhydrochlorid-zusammensetzungen
RU2224518C1 (ru) * 2003-02-10 2004-02-27 Дулькис Мария Дмитриевна Жидкая лекарственная форма налтрексона
HRP20150037T4 (hr) 2003-04-08 2022-09-02 Progenics Pharmaceuticals, Inc. Farmaceutske formulacije koje sadrže metilnaltrekson
RU2238093C1 (ru) * 2003-08-07 2004-10-20 Государственный научный центр вирусологии и биотехнологии "Вектор" Фторированные производные 2-ароил-3-метил-6,7-дифторбенз[4,5]-имидазо[1,2-b][1,3]-тиазолов-ингибитор ы репродукции вируса кори
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
ES2714198T3 (es) 2005-03-07 2019-05-27 Univ Chicago Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
SI2565195T1 (sl) 2007-03-29 2015-09-30 Wyeth Llc Periferalni opioidni receptorji in antagonisti in njih uporaba
CL2008000905A1 (es) 2007-03-29 2008-08-22 Progenics Pharm Inc Compuestos derivados de morfina, antagonistas del receptor opioide periferico; metodo de preparacion; composicion farmaceutica; y uso para reducir los efectos de la actividad opioide endogena.
MX2009010550A (es) 2007-03-29 2009-12-14 Progenics Pharm Inc Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas.
EP2240489A1 (en) 2008-02-06 2010-10-20 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
EP2278966B1 (en) 2008-03-21 2019-10-09 The University of Chicago Treatment with opioid antagonists and mtor inhibitors
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
EP3939570A1 (en) * 2016-02-18 2022-01-19 Immune Therapeutics, Inc. Naltrexone for treating or preventing autoimmune and inflammatory diseases
US11285192B2 (en) 2019-03-13 2022-03-29 Adamis Pharmaceuticals Corporation Formulation including a combination of beta-endorphin and adrenocorticotropic hormone
SG11202109652TA (en) * 2019-03-13 2021-10-28 Adamis Pharmaceuticals Corp FORMULATION INCLUDING A COMBINATION OF ß-ENDORPHIN AND ADRENOCORTICOTROPIC HORMONE

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3332950A (en) * 1963-03-23 1967-07-25 Endo Lab 14-hydroxydihydronormorphinone derivatives

Also Published As

Publication number Publication date
DE3851711D1 (de) 1994-11-10
AU1189688A (en) 1988-08-10
OA09124A (fr) 1991-10-31
FR2609632A1 (fr) 1988-07-22
EP0278821B1 (fr) 1994-10-05
EP0278821A1 (fr) 1988-08-17
DK524788D0 (da) 1988-09-21
FR2609632B1 (fr) 1991-03-29
AU610561B2 (en) 1991-05-23
WO1988005297A1 (fr) 1988-07-28
JPH02502278A (ja) 1990-07-26
ATE112488T1 (de) 1994-10-15

Similar Documents

Publication Publication Date Title
DK524788D0 (da) Anvendelse af morphin-antagonister til fremstilling af laegemidler med immunomodulerende og antiviral effekt, isaer til behandling af erhvervede immundefekt-tilstande
DK0509019T3 (da) Behandling af humane retrovirale infektioner med 2',3'-dideoxyinosin
DK162965C (da) Anvendelse af et difluornucleosid eller et farmaceutisk acceptabelt salt deraf til fremstilling af et laegemiddel til behandling af neoplasma
ES2149267T3 (es) Carbonilos ciclicos substituidos y derivados de los mismos utiles como inhibidores de la proteasa retroviral.
ES2130114T3 (es) 5,11-dihidro-6h-dipirido(3,2-b:2',3'-e)(1,4)diazepinas y su uso en la prevencion o tratamiento de infeccion por hiv.
DK602988D0 (da) Nukleosidderivater med antiviral virkning og laegemiddelpraeparat indeholdende saadanne forbindelser
DK336688D0 (da) Nucleosider od fremgangsmaade til fremstilling deraf
ZA913033B (en) N-(3-fluoro-2-phosphonylmethoxypropyl)derivatives of purine and pyrimidine heterocyclic basis,their preparation and use
DK92788A (da) Anvendelse af 3'-deoxy-3'-flourguanosider til fremstilling af laegemidler mod retrovira
DK422589D0 (da) Farmaceutisk praeparat til behandling af immundefekttilstande
DK557087A (da) Forbindelse til behandling af retrovirusinfektioner
DK538888A (da) Anvendelse af castanosperminestere til fremstilling af et farmaceutisk praeparat
ATE132163T1 (de) Neue polypeptide und damit hergestellte anti-hiv medikamente
TW371662B (en) Antiviral acyclic phosphonomethoxyalkyl substituted alkenyl purine and pyrimidine derivatives
DE3788338D1 (de) Vorbehandlungswirkstoff zur perkutanen verabreichung.
IT8621397A0 (it) Derivati del pirrolidin-2-one adattivita' nootropa.
ATE108335T1 (de) Kit oder zusammensetzung zur vorbeugung oder behandlung von hiv-1 infektionen.
IT1225262B (it) Metodo per la sensibilizzazione di piccoli animali all'infezione da virus dell'immunodeficienza umana (hiv)
ES2066897T3 (es) 5,11-dihidro-6h-pirido(2,3-b)(1,4)benzodiazepin-6-onas y -tionas y su uso en la prevencion o el tratamiento del sida.
DK469487A (da) Laegemiddel til behandling af fedme
FI862412L (fi) Anordning foer omraodet av draget med enkel vira i flercylindertorken av en pappersmaskin.
ATE79529T1 (de) Vorrichtung zur stimulation von gliedversteifungen.
DE69010736D1 (de) Anti-HIV Zusammensetzungen.
IT8720402A0 (it) Procedimento per la preparazione di derivati condensati as-triazinici.
IT8723272A0 (it) Derivati pirimidinici condensati e procedimento per la loro preparazione.

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment